CoChat
Sign Up
Cited by 1,372Glioma Diagnosis and TreatmentAngiogenesis and VEGF in CancerOvarian cancer diagnosis and treatment

Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma

Open access
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., Olson, J. J.·2010·CA: A Cancer Journal for Clinicians
DOI 10.3322/caac.20069PMC PMC2888474
Open this paper in CoChat — free account

Abstract

Malignant gliomas are the most common and deadly brain tumors. Nevertheless, survival for patients with glioblastoma, the most aggressive glioma, although individually variable, has improved from an average of 10 months to 14 months after diagnosis in the last 5 years due to improvements in the standard of care. Radiotherapy has been of key importance to the treatment of these lesions for decades, and the ability to focus the beam and tailor it to the irregular contours of brain tumors and minimize the dose to nearby critical structures with intensity-modulated or image-guided techniques has improved greatly. Temozolomide, an alkylating agent with simple oral administration and a favorable toxicity profile, is used in conjunction with and after radiotherapy. Newer surgical techniques, such as fluorescence-guided resection and neuroendoscopic approaches, have become important in the management of malignant gliomas. Furthermore, new discoveries are being made in basic and translational research, which are likely to improve this situation further in the next 10 years. These include agents that block 1 or more of the disordered tumor proliferation signaling pathways, and that overcome resistance to already existing treatments. Targeted therapies such as antiangiogenic therapy with antivascular endothelial growth factor antibodies (bevacizumab) are finding their way into clinical practice. Large-scale research efforts are ongoing to provide a comprehensive understanding of all the genetic alterations and gene expression changes underlying glioma formation. These have already refined the classification of glioblastoma into 4 distinct molecular entities that may lead to different treatment regimens. The role of cancer stem-like cells is another area of active investigation. There is definite hope that by 2020, new cocktails of drugs will be available to target the key molecular pathways involved in gliomas and reduce their mortality and morbidity, a positive development for patients, their families, and medical professionals alike.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3322/caac.20069

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 119

  1. [1]Stieber VW Mehta MP Advances in radiation therapy for brain tumors Neurol Clin 2007 25 1005 1033 17964024
  2. [2]Westphal M Hilt DC Bortey E A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro Oncol 2003 5 79 88 12672279 PMC1920672
  3. [3]Brem H Piantadosi S Burger PC Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet 1995 345 1008 1012 7723496
  4. [5]Norden AD Young GS Setayesh K Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 2008 70 779 787 18316689
  5. [6]Noda SE El-Jawahri A Patel D Lauten-schlaeger T Siedow M Chakravarti A Molecular advances of brain tumors in radiation oncology Semin Radiat Oncol 2009 19 171 178 19464632
  6. [7]Hegi ME Diserens AC Gorlia T MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 2005 352 997 1003 15758010
  7. [8]Paez-Ribes M Allen E Hudock J Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 2009 15 220 231 19249680 PMC2874829
  8. [9]Tuettenberg J Grobholz R Seiz M Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy J Cancer Res Clin Oncol 2009 135 1239 1244 19277712 PMC12160220
  9. [10]Carson KA Grossman SA Fisher JD Shaw EG Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials J Clin Oncol 2007 25 2601 2606 17577040 PMC4118746
  10. [11]Sulman EP Guerrero M Aldape K Van Meir EG Transcription profiling of brain tumors: tumor biology and treatment stratification CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 529 552
  11. [12]Schneider BP Radovich M Miller KD The role of vascular endothelial growth factor genetic variability in cancer Clin Cancer Res 2009 15 5297 5302 19706811
  12. [13]The Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 2008 455 1061 1068 18772890 PMC2671642
  13. [14]Hadjipanayis CG Van Meir EG Brain cancer propagating cells: biology, genetics and targeted therapies Trends Mol Med 2009 14 519 530 19889578 PMC2782740
  14. [15]Hadjipanayis CG Van Meir EG Tumor initiating cells in malignant gliomas: biology and implications for therapy J Mol Med 2009 87 363 374 19189072 PMC2693383
  15. [16]Bachoo RM Maher EA Ligon KL Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis Cancer Cell 2002 1 269 277 12086863
  16. [17]Brat DJ Van Meir EG Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma Lab Invest 2004 84 397 405 14990981
  17. [18]Libermann TA Nusbaum HR Razon N Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin Nature 1985 313 144 147 2981413
  18. [19]James CD Carlbom E Nordenskjold M Collins VP Cavenee WK Mitotic recombination of chromosome 17 in astrocytomas Proc Natl Acad Sci U S A 1989 86 2858 2862 2565039 PMC287018
  19. [20]Yin S Van Meir EG Van Meir EG p53 pathway alterations in brain tumors CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 283 314
  20. [21]Stokoe D Furnari FB Van Meir EG The PTEN/PI3 kinase pathway in human glioma CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 315 357
  21. [24]Belozerov VE Van Meir EG Inhibitors of hypoxia-inducible factor-1 signaling Curr Opin Investig Drugs 2006 7 1067 1076 17209524
  22. [26]Misra A Feuerstein BG Van Meir EG Discovery of genetic markers for brain tumors by comparative genomic hybridization CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009
  23. [28]Wen PY Kesari S Malignant gliomas in adults N Engl J Med 2008 359 492 507 18669428
  24. [29]Gerstner ER Batchelor TT Van Meir EG Clinical agents for the targeting of brain tumor vasculature CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 731 728
  25. [31]Bellail AC Mulligan P Hao C Van Meir EG Targeting of TRAIL apoptotic pathways for glioblastoma therapies CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 977 1010
  26. [32]Li YC Tzeng CC Song JH Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy Clin Cancer Res 2006 12 2716 2729 16675563
  27. [33]Laver T Nozell S Benveniste EN Van Meir EG The NF-kB signaling pathway in GBMs: implications for apoptotic and inflammatory responses and exploitation for therapy CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 1011 1036
  28. [34]Hwang Y Latha K Gururaj A Rojas M Bogler O Van Meir EG Aberrant EGFR signaling in glioma CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 441 459
  29. [35]Thiessen B Stewart C Tsao M A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation Cancer Chemother Pharmacol 2010 65 353 361 19499221
  30. [36]Neyns B Sadones J Joosens E Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma Ann Oncol 2009 20 1596 1603 19491283
  31. [37]Mellinghoff IK Wang MY Vivanco I Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 2005 353 2012 2024 16282176
  32. [39]van den Bent MJ Brandes AA Rampling R Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 J Clin Oncol 2009 27 1268 1274 19204207 PMC2667826
  33. [40]Assanah M Lopez KA Bruce JN Canoll P Van Meir EG Modeling gliomas using PDGF-expressing retroviruses CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 3 27
  34. [41]Kilic T Alberta JA Zdunek PR Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class Cancer Res 2000 60 5143 5150 11016641
  35. [42]Wen PY Yung WK Lamborn KR Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08 Clin Cancer Res 2006 12 4899 4907 16914578
  36. [43]Chang SM Wen P Cloughesy T Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme Invest New Drugs 2005 23 357 361 16012795
  37. [44]Galanis E Buckner JC Maurer MJ Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study J Clin Oncol 2005 23 5294 5304 15998902
  38. [45]Kreisl TN Kim L Moore K A phase I trial of enzastaurin in patients with recurrent gliomas Clin Cancer Res 2009 15 3617 3623 19417015 PMC7227612
  39. [46]Cloughesy TF Wen PY Robins HI Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study J Clin Oncol 2006 24 3651 3656 16877733
  40. [47]Galanis E Jaeckle KA Maurer MJ Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study J Clin Oncol 2009 27 2052 2058 19307505 PMC2669764
  41. [48]Atkinson JM Gilbertson RJ Rich JN Van Meir EG Brain cancer stem cells as targets of novel therapies CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 1157 1175
  42. [49]Stommel JM Kimmelman AC Ying H Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 2007 318 287 290 17872411
  43. [50]Reardon DA Desjardins A Vredenburgh JJ Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma J Neurooncol 2010 96 219 230 19562254 PMC2844073
  44. [52]Cloughesy TF Yoshimoto K Nghiemphu P Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Med 2008 5 e8 18215105 PMC2211560
  45. [53]Jain RK di Tomaso E Duda DG Loeffler JS Sorensen AG Batchelor TT Angiogenesis in brain tumours Nat Rev Neurosci 2007 8 610 622 17643088
  46. [54]Bergers G Van Meir EG Bone marrow-derived cells in GBM neovascularization CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 749 773
  47. [55]Schmidt NO Westphal M Hagel C Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis Int J Cancer 1999 84 10 18 9988225
  48. [56]Hu B Guo P Bar-Joseph I Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway Oncogene 2007 26 5577 5586 17369861 PMC2846324
  49. [57]Holash J Maisonpierre PC Compton D Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 1999 284 1994 1998 10373119
  50. [58]Oliner J Min H Leal J Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 Cancer Cell 2004 6 507 516 15542434
  51. [59]Noguera-Troise I Daly C Papadopoulos NJ Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis Nature 2006 444 1032 1037 17183313
  52. [61]Narayana A Kelly P Golfinos J Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival J Neurosurg 2009 110 173 180 18834263
  53. [62]Nghiemphu PL Liu W Lee Y Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience Neurology 2009 72 1217 1222 19349600 PMC2677488
  54. [63]Poulsen HS Grunnet K Sorensen M Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours Acta Oncol 2009 48 52 58 19031176
  55. [64]Zuniga RM Torcuator R Jain R Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan J Neurooncol 2009 91 329 336 18953493
  56. [65]Guiu S Taillibert S Chinot O Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF multi-center study Rev Neurol (Paris) 2008 164 588 594 18565358
  57. [66]Pope WB Lai A Nghiemphu P Mischel P Cloughesy TF MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology 2006 66 1258 1260 16636248
  58. [68]Vredenburgh JJ Desjardins A Herndon JE 2nd Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Abstract J Clin Oncol 2007 25 4722 4729 17947719
  59. [69]Yung WK Prados MD Yaya-Tur R Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group J Clin Oncol 1999 17 2762 2771 10561351
  60. [70]Friedman HS Prados MD Wen PY Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 2009 27 4733 4740 19720927
  61. [72]Kreisl TN Kim L Moore K Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 2009 27 740 745 19114704 PMC2645088
  62. [73]Batchelor TT Sorensen AG di Tomaso E AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 2007 11 83 95 17222792 PMC2748664
  63. [74]Sorensen AG Batchelor TT Zhang WT A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res 2009 69 5296 5300 19549889 PMC2824172
  64. [75]Guo P Hu B Gu W Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment Am J Pathol 2003 162 1083 1093 12651601 PMC1851242
  65. [76]Avraamides CJ Garmy-Susini B Varner JA Integrins in angiogenesis and lymphangiogenesis Nat Rev Cancer 2008 8 604 617 18497750 PMC2577722
  66. [78]Lamszus K Kunkel P Westphal M Invasion as limitation to anti-angiogenic glioma therapy Acta Neurochir Suppl 2003 88 169 177 14531575
  67. [79]Erber R Thurnher A Katsen A Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 2004 18 338 340 14657001
  68. [80]Bellail AC Hunter SB Brat DJ Tan C Van Meir EG Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion Int J Biochem Cell Biol 2004 36 1046 1069 15094120
  69. [81]Viapiano MS Lawler SE Van Meir EG Glioma invasion: mechanisms and targeting opportunities CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 1219 1252
  70. [82]Walker PR Prins RM Dietrich P-Y Liau LM Van Meir EG Harnessing T-cell immunity to target brain tumors CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 1165 1217
  71. [83]Desbaillets I Diserens AC Tribolet N Hamou MF Van Meir EG Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis J Exp Med 1997 186 1201 1212 9334359 PMC2199083
  72. [84]Ayriss JE Kuan C-T Boulton ST Reardon DA Bigner DD Van Meir EG Molecular targets for antibody-mediated immunotherapy of malignant glioma CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 865 898
  73. [85]Stewart LA Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 2002 359 1011 1018 11937180
  74. [86]Rivera AL Pelloski CE Gilbert MR Colman H De La Cruz C Sulman EP Bekele BN Aldape KD MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Neuro Oncol 2010 12 116 121 20150378 PMC2940581
  75. [87]Tolcher AW Gerson SL Denis L Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 2003 88 1004 1011 12671695 PMC2376384
  76. [88]Broniscer A Gururangan S MacDonald TJ Phase I trial of single-dose temozolomide and continuous administration of O6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report Clin Cancer Res 2007 13 6712 6718 18006772
  77. [89]Donawho CK Luo Y Penning TD ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin Cancer Res 2007 13 2728 2737 17473206
  78. [90]Khwaja FW Van Meir EG Van Meir EG Proteomic discovery of biomarkers in the cerebrospinal fluid of brain tumor patients CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 1 New York Humana Press (Springer) 2009 577 614
  79. [91]Khwaja FW Reed MS Olson JJ Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients J Proteome Res 2007 6 559 570 17269713 PMC2566942
  80. [92]Van Meir EG Sawamura Y Diserens A-C Hamou M-F de Tribolet N Human glioblastoma cells release interleukin 6 in vivo and in vitro Cancer Res 1990 50 6683 6688 2208133
  81. [93]Van Meir E Ceska M Effenberger F Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system Cancer Res 1992 52 4297 4305 1643627
  82. [94]Kuratsu J Yoshizato K Yoshimura T Leonard EJ Takeshima H Ushio Y Quantitative study of monocyte chemoattrac-tant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma J Natl Cancer Inst 1993 85 1836 1839 8230263
  83. [95]Frei K Piani D Malipiero UV Van Meir EG de Tribolet N Fontana A Granulocyte–macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells: despite the presence of inducing signals GM-CSF is not expressed in vivo J Immunol 1992 148 3140 3146 1315829
  84. [96]Desbaillets I Tada M de Tribolet N Diserens AC Hamou MF Van Meir EG Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro Int J Cancer 1994 58 240 247 7517920
  85. [97]Khwaja F Duke-Cohan JS Brat DJ Van Meir EG Attractin is elevated in the cerebrospinal fluid (CSF) of patients with malignant astrocytoma and mediates glioma cell migration Clin Cancer Res 2006 12 6331 6336 17085642
  86. [98]Cappabianca P Cinalli G Gangemi M Application of neuroendoscopy to intra-ventricular lesions Neurosurgery 2008 62 suppl 2 575 597 18596446
  87. [99]Souweidane MM Luther N Endoscopic resection of solid intraventricular brain tumors J Neurosurg 2006 105 271 278 17219833
  88. [100]Greenlee JD Teo C Ghahreman A Kwok B Purely endoscopic resection of colloid cysts Neurosurgery 2008 62 51 55 18424967
  89. [101]Hopf NJ Grunert P Fries G Resch KD Perneczky A Endoscopic third ventriculostomy: outcome analysis of 100 consecutive procedures Neurosurgery 1999 44 795 804 10201305
  90. [102]Lekovic GP Gonzalez LF Feiz-Erfan I Rekate HL Endoscopic resection of hypothalamic hamartoma using a novel variable aspiration tissue resector Neurosurgery 2006 58 ONS166 ONS169 16543875
  91. [103]Sanai N Berger MS Glioma extent of resection and its impact on patient outcome Neurosurgery 2008 62 753 764 18496181
  92. [104]Vuorinen V Hinkka S Farkkila M Jaaskelainen J Debulking or biopsy of malignant glioma in elderly people - a randomised study Acta Neurochir (Wien) 2003 145 5 10 12545256
  93. [105]Tonn JC Stummer W Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls Clin Neurosurg 2008 55 20 26 19248665
  94. [106]Stummer W Pichlmeier U Meinel T Wiestler OD Zanella F Reulen HJ Fluorescence-guided surgery with 5-aminole-vulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial Lancet Oncol 2006 7 392 401 16648043
  95. [107]Hadjipanayis CG Bonder MJ Balakrishnan S Wang X Mao H Hadjipanayis GC Metallic iron nanoparticles for MRI contrast enhancement and local hyperthermia Small 2008 4 1925 1929 18752211 PMC2709953
  96. [108]Walker MD Strike TA Sheline GE An analysis of dose-effect relationship in the radiotherapy of malignant gliomas Int J Radiat Oncol Biol Phys 1979 5 1725 1731 231022
  97. [109]Chan MF Schupak K Burman C Chui CS Ling CC Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme Med Dosim 2003 28 261 265 14684191
  98. [110]McDonald MW Shu HG Curran WJ Crocker IR Pattern of failure after limited margin radiotherapy and temozolomide in glioblastoma Int J Radiat Oncol Biol Phys 2010 In Press 20399036
  99. [111]Lawson JD Fox T Elder E Early clinical experience with kilovoltage image-guided radiation therapy for interfraction motion management Med Dosim 2008 33 268 274 18973853
  100. [112]Tsao MN Mehta MP Whelan TJ The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma Int J Radiat Oncol Biol Phys 2005 63 47 55 16111571
  101. [113]Souhami L Seiferheld W Brachman D Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol Int J Radiat Oncol Biol Phys 2004 60 853 860 15465203
  102. [114]Larson DA Prados M Lamborn KR Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma Int J Radiat Oncol Biol Phys 2002 54 1397 1404 12459362
  103. [115]Combs SE Widmer V Thilmann C Hof H Debus J Schulz-Ertner D Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM) Cancer 2005 104 2168 2173 16220556
  104. [116]Adler JR Jr Chang SD Murphy MJ Doty J Geis P Hancock SL The Cyberknife: a frameless robotic system for radiosurgery Stereotact Funct Neurosurg 1997 69 124 128 9711744
  105. [117]Meeks SL Tome WA Willoughby TR Optically guided patient positioning techniques Semin Radiat Oncol 2005 15 192 201 15983944
  106. [118]Wurm RE Erbel S Schwenkert I Novalis frameless image-guided noninvasive radiosurgery: initial experience Neurosurgery 2008 62 suppl 5 A11 A17 18580775
  107. [119]Fitzek MM Thornton AF Rabinov JD Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial J Neurosurg 1999 91 251 260 10433313
  108. [120]Chan JL Lee SW Fraass BA Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy J Clin Oncol 2002 20 1635 1642 11896114
  109. [121]Nelson DF Diener-West M Weinstein AS A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study Int J Radiat Oncol Biol Phys 1986 12 1793 1800 3531110
  110. [122]Prados MD Seiferheld W Sandler HM Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404 Int J Radiat Oncol Biol Phys 2004 58 1147 1152 15001257
  111. [123]van Nifterik KA van den Berg J Stalpers LJ Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines Int J Radiat Oncol Biol Phys 2007 69 1246 1253 17967314
  112. [124]O’Rourke DM Kao GD Singh N Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells Proc Natl Acad Sci U S A 1998 95 10842 10847 9724792 PMC27983
  113. [125]Li B Yuan M Kim IA Chang CM Bernhard EJ Shu HK Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes ra-dioresistance in cells of astrocytic origin Oncogene 2004 23 4594 4602 15077177
  114. [126]Gerstner ER Sorensen AG Jain RK Batchelor TT Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas Curr Opin Neurol 2008 21 728 735 18989120
  115. [127]Ogawa T Shishido F Kanno I Cerebral glioma: evaluation with methionine PET Radiology 1993 186 45 53 8380108
  116. [128]Shoup TM Olson J Hoffman JM Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors J Nucl Med 1999 40 331 338 10025843
  117. [129]Chen W Cloughesy T Kamdar N Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG J Nucl Med 2005 46 945 952 15937304
  118. [130]Cher LM Murone C Lawrentschuk N Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies J Nucl Med 2006 47 410 418 16513609
  119. [131]Martin M Laser accelerated radiotherapy: is it on its way to the clinic? J Natl Cancer Inst 2009 101 450 451 19318637

Cited by

Sorted by citations

Authors
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J.
Affiliations
  • Emory University (US)
  • Brigham and Women's Hospital (US)
ORCID
Venue
CA: A Cancer Journal for Clinicians
Publisher
Wiley
Published
2010-05-01
Volume
60
Issue
3
Pages
166-193
ISSN
0007-9235 (ISSN-L)
DOI
10.3322/caac.20069
PMC
PMC2888474
OpenAlex
W2115862526
Cited by
1,372
References
8
Citations by year
2026: 7 · 2025: 33 · 2024: 63 · 2023: 72 · 2022: 93 · 2021: 96 · 2020: 97 · 2019: 100 · 2018: 97 · 2017: 99 · 2016: 80 · 2015: 98 · 2014: 104 · 2013: 97 · 2012: 127
FWCI
47.57
Type
journal article
Language
en
Open access
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1949 d)
Locations
  • CA A Cancer Journal for Clinicians (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (CA86335, CA116804, R01CA116804, R01CA086335)
  • National Institute of Neurological Disorders and Stroke (NS053454, K08NS053454)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Keywords
high-grade glioma, glioblastoma, temozolomide, radiotherapy, intensity-modulated radiotherapy, image-guided radiotherapy, fluorescence-guided resection, targeted therapy, anti-angiogenic therapy, bevacizumab, vascular endothelial growth factor, glioma molecular classification, cancer stem-like cells, drug resistance
MeSH terms
Antineoplastic Agents, Brain Neoplasms, Epidermal Growth Factor, Glioblastoma, Humans, Molecular Biology, Biomarkers, Tumor, Signal Transduction, Apoptosis, Treatment Failure, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review